ClinicalTrials.gg
RecruitingNCT06492148Updated Nov 21, 2024

Myofascial Release Technique in Women With Primary Dysmenorrhea

An interventional study of Myofascial Release and Sham-Myofascial Release in Dysmenorrhea Primary, Central Sensitisation and Myofascial Trigger Point Pain, sponsored by Gazi University. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Gazi University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Myofascial Pain Syndromes with a site in Turkey — 12 open to participants now, 12 under way, none of them phase 3. Myofascial Pain Syndromes · Turkey.

Planned enrollment
58th of 67
36 · median 60
Started
2024
with 8 others
No phase
62 of 81
8 open now
Primary completion
2024-12
later than 1 of 11 live
Registered
52nd of 81
by date

Among the 81 studies in Myofascial Pain Syndromes with a site in Turkey, this one is the 58th largest by planned enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2024, is one of 62 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 52nd registered.

Myofascial Pain Syndromes

340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.

Browse Myofascial Pain Syndromes studies →

Open to participants now

12 of the 81 studies in Myofascial Pain Syndromes with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 35 Myofascial Pain Syndromes studies recruiting now, 6 (17%) set no upper age limit and 26 (74%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Myofascial Pain Syndromes with a site in Turkey, or all of them as a file.
02

Study summary

It has been found that women with dysmenorrhea have active trigger points, particularly in the rectus abdominis, oblique abdominal muscles, quadratus lumborum, and paraspinal muscles. The myofascial release technique is a widely used manual therapy method characterized by the application of low-load, long-duration mechanical forces to manipulate the myofascial complex. This technique aims to restore optimal length, alleviate pain, and improve function. This study aims to examine the effect of the myofascial release technique on central sensitization, myofascial trigger points, and menstrual symptoms in women with primary dysmenorrhea.

Read the detailed description

During the evaluation period, the participants' musculoskeletal pain threshold and tolerance will be measured using an algometer, about trigger points on the identified muscles (rectus abdominis, quadratus lumborum, erector spinae, and tibialis anterior). A total of 40 women, aged 18-40, diagnosed with primary dysmenorrhea by a gynecologist, will be included in the study. The initial assessment of the participants will be conducted on their most painful days. Participants will be randomized into two groups: the myofascial release technique group (study group) and the placebo myofascial release technique group (control group). The interventions will be conducted over 10 sessions during one menstrual cycle, and all evaluations will be repeated after the treatment period. The study will be conducted as a double-blind trial, ensuring that both the evaluators and the patients are blind to the group assignments.

03

Conditions studied

  • Dysmenorrhea Primary
  • Central Sensitisation
  • Myofascial Trigger Point Pain
  • Menstrual Discomfort
  • Myofascial Release

Keywords

  • myofascial release
  • trigger point
  • Central sensitization
  • Dysmenorrhea
  • sham
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Primary Dysmenorrhea according to the Primary Dysmenorrhea Consensus Guide,
  • Having regular menstruation in the last 6 months (28±7 days)
  • Those who had menstrual pain between 40 mm and 100 mm according to the Visual Analogue Scale (VAS) in the last 6 months

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with Secondary Dysmenorrhea,
  • Having given birth,
  • Those with serious gastrointestinal, urogynecological, or diseases or other chronic pain syndromes,
  • Undergoing urogynecological surgery,
  • Those who are pregnant or suspected of pregnancy,
  • Those who use analgesics or non-pharmacological agents other than NSAIDs for menstrual pain,
  • Those using intrauterine or oral ,
  • Those taking extra supplements such as magnesium, which may affect treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Myofascial Release Group

    The technique known as myofascial release, also referred to as cross-hand release, will be applied to 7 regions. Among these regions are the lateral abdominal wall (right and left), the lower abdomen with the opposite side medial thigh (right and left crossed), the thoracolumbar fascia (bilateral), and the lumbosacral region. In the cross-hand technique, hands will be gently placed on the specified regions and directions. The release of the barriers of the tissue under the hands will be ensured, and the technique will be applied until a wave or oscillation is felt. A myofascial release technique with an optimal duration of 5 minutes will be applied to each region. The total treatment time will be 35 minutes.

    Other: Myofascial Release

  • Sham comparator
    Sham- Myofascial Release Group

    The hands of the researcher applying the technique will be positioned on the same regions as the myofascial release technique, with only the palms lightly touching for the same duration. However, there will be no intervention aimed at applying pressure or opening tissue barriers. The total sham treatment time will be 35 minutes.

    Other: Sham-Myofascial Release

Interventions

  • OtherMyofascial Release

    The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.

  • OtherSham-Myofascial Release

    The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.

06

What researchers measure

Primary outcomes

  1. Pain Pressure Threshold

    Trigger points in specific muscles (rectus abdominis, paraspinal muscles, quadratus lumborum, gluteus maximus) will be determined. Then, it will be applied to the trigger points with the Baseline brand algometer in accordance with standard procedures and the pressure will be increased by 30 kPa/s.

    Time frame: Baseline (First menstruation cycle)

  2. Pain Pressure Threshold

    Trigger points in specific muscles (rectus abdominis, paraspinal muscles, quadratus lumborum, gluteus maximus) will be determined. Then, it will be applied to the trigger points with the Baseline brand algometer in accordance with standard procedures and the pressure will be increased by 30 kPa/s.

    Time frame: through study completion, an average of 3 months

  3. Central Sensitization

    Pain threshold will be measured with an algometer at a certain point of the tibialis muscle.

    Time frame: Baseline (First menstruation cycle)

  4. Central Sensitization

    Pain threshold will be measured with an algometer at a certain point of the tibialis muscle.

    Time frame: through study completion, an average of 3 months

  5. Menstrual pain intensity

    Menstrual pain intensity will be determined by a 10 cm Visual Analog Scale ranging from zero (no pain at all) to 10 (worst pain I have ever felt). Higher scores mean worse conditions. Participants will be asked to mark the severity of pain they felt in the first 3 days of their last menstrual bleeding on 3 separate lines.

    Time frame: Baseline (First menstruation cycle)

  6. Menstrual pain intensity

    Menstrual pain intensity will be determined by a 10 cm Visual Analog Scale ranging from zero (no pain at all) to 10 (worst pain I have ever felt). Higher scores mean worse conditions. Participants will be asked to mark the severity of pain they felt in the first 3 days of their last menstrual bleeding on 3 separate lines.

    Time frame: through study completion, an average of 3 months

Secondary outcomes

  1. Menstrual Attitude

    Menstrual Attitude Scale will be used to evaluate symptoms related to menstruation. High scores indicate a high awareness of menstruation.

    Time frame: Baseline (First menstruation cycle)

  2. Menstrual Attitude

    Menstrual Attitude Scale will be used to evaluate symptoms related to menstruation. High scores indicate a high awareness of menstruation.

    Time frame: through study completion, an average of 3 months

  3. Health-related quality of life

    Short Form (SF-36) will be used to evaluate individuals' general health-related quality of life. SF-36 is a 36-question survey that evaluates functionality and well-being and consists of 8 subscales. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Higher scores indicate a better quality of life.

    Time frame: Baseline (First menstruation cycle)

  4. Health-related quality of life

    SF-36 will be used to evaluate individuals' general health-related quality of life. SF-36 is a 36-question survey that evaluates functionality and well-being and consists of 8 subscales. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Higher scores indicate a better quality of life.

    Time frame: through study completion, an average of 3 months

  5. Anxiety

    State and Trait Anxiety Scale is a self-assessment inventory that evaluates anxiety and consists of 40 items.

    Time frame: Baseline (First menstruation cycle)

  6. Anxiety

    State and Trait Anxiety Scale is a self-assessment inventory that evaluates anxiety and consists of 40 items.

    Time frame: through study completion, an average of 3 months

  7. The Body Awareness

    The Body Awareness Questionnaire will be used to evaluate changes in individuals' body awareness. The questionnaire consists of 18 items and 4 subscales (predicting body reactions, sleep-wake cycle, predicting the onset of the disease, paying attention to changes in body processes).

    Time frame: Baseline (First menstruation cycle)

  8. The Body Awareness

    The Body Awareness Questionnaire will be used to evaluate changes in individuals' body awareness. The questionnaire consists of 18 items and 4 subscales (predicting body reactions, sleep-wake cycle, predicting the onset of the disease, paying attention to changes in body processes).

    Time frame: through study completion, an average of 3 months

07

Study locations

1 of 1 sites recruiting
  • Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Gazi University
    Ankara, 06530, Turkey
    Recruiting
    • Beyza Yazgan Dagli · Contactbeyzayazgan@gazi.edu.tr
    • Beyza Yazgan Dagli · Principal investigator
    • Sevim B Olmez · Principal investigator
    • Zeynep B Alkan · Principal investigator
    • Zeynep Hazar Kanık · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2024, 2 months after the start.

Of 203 non-industry interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's planned 2 months is below that.

Counting every sponsor, half of 205 studies reached it within 5 months; a quarter within 2 and three quarters within 13.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jul 9, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Dec 2, 2024
CompletionEst.
Sep 25, 2025
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492148
Lead sponsor
Gazi University
Responsible party
BEYZA YAZGAN DAĞLI (Research Assistant, Gazi University) — Principal investigator
First posted
Jul 9, 2024
Start date
Sep 10, 2024
Primary completion
Dec 2, 2024 (estimated)
Completion
Sep 25, 2025 (estimated)
Last update
Nov 21, 2024

Study contacts

Research Asisstant
Contact
beyzayazgan@gazi.edu.tr
+905535134631
Beyza Yazgan Dagli
principal investigator · Gazi University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion